Fifteen minutes can mean life and death for stroke victims. The new stroke treatment breakthrough which was used to treat Alzheimers disease can now give new hope to stroke survivors. According to a new study published in the Journal of the American Medical Association June 19 issue, rapid clot-dissolving drug treatment will reduce the patient’s death risk and increase their chance of walking and returning home when they leave the hospital.
In a journal news release, Dr Jeffrey Saver of the David Geffen School of Medicine at the University of California, Los Angeles said that the findings supported intensive efforts to accelerate patient presentation and streamline hospital systems to compress times with acute stroke care.
Researchers examined the data of more than 58,000 patients suffering from ischemic stroke with blocked blood flow to the brains treated in 1,400 U.S. hospitals between 2003 and 2012, with plasminogen activators (tPA) within four and a half hours of stroke symptom’s onset. Nine percent of patients were treated within 90 minutes of the symptom onset, 77 percent treated within 91 and 180 minutes and 14 percent treated in181 to 270 minutes. Researchers found that approximately 9 percent of the patients died in the hospital, 5 percent had intracranial ambulance; 33 percent could walk home when released from a hospital, and 38 percent were discharged to their home.
Factors strongly associated with shorter onset-to-treatment time pose greater stroke severity, meaning, for every 15-minute tPA therapy, stroke patients are unlikely to die and have intracranial hemorrhage. For instance, 26 percent of patients are less likely to die if treatment time is 90 minutes, 28 percent are may not have intracranial hemorrhage; 51 percent are more linclined to walk, and 33 percent are more likely to be discharge compared to those treated 181 to 270 minutes later.
A single perispinal injection of Enbrel (Etanercept) can reduce impairment significantly. Neurological Wellness Center in Managua, Nicaragua began teaching physicians, nurses, and caregivers the perispinal injection technique and has been facilitating patients recovering from stroke since 2010. The center conducted a study in 629 patients with TBI (traumatic brain injury), and stroke treated with Etanercept and confirmed the efficacy of perispinally injected Enbrel.
Patients suffering from TBI and stroke treated after 42 months showed significant rapid improvement in cognitive and motor impairment, which was a radical breakthrough in medical treatment.
The perispinal Enbrel is also effective as Alzheimer’s treatment with the maximum recommended dose of 25mg/week for life. For the stroke victim, their complete treatment recommendation is one 25mg injection of Enbrel every four days for a total of four doses over 16 days, and for TBI one 25mg injection every four days for eight doses.
The drug Enbrel received FDA approval in 1998, but it was not until recently that this treatment was confirmed to give new hope to stroke survivors. Enbrel must be administered at the back of the neck for it to treat stroke, Alzheimer’s, and TBI to allow it to enter the brain by lymph drainage assisted by gravity.
Written by: Janet Grace Ortigas